SOPHiA GENETICS SA (NASDAQ:SOPH) Short Interest Update

SOPHiA GENETICS SA (NASDAQ:SOPH) was the recipient of a significant drop in short interest in the month of December. As of December 15th, there was short interest totaling 32,434 shares, a drop of 26.5% from the November 30th total of 44,138 shares. Approximately 0.1% of the company’s shares are short sold. Based on an average daily volume of 99,157 shares, the days-to-cover ratio is currently 0.3 days. Based on an average daily volume of 99,157 shares, the days-to-cover ratio is currently 0.3 days. Approximately 0.1% of the company’s shares are short sold.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently commented on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of SOPHiA GENETICS in a research report on Wednesday, October 8th. Wall Street Zen raised SOPHiA GENETICS to a “hold” rating in a research note on Saturday, November 1st. Finally, BTIG Research lifted their price objective on SOPHiA GENETICS from $6.00 to $7.00 and gave the stock a “buy” rating in a research note on Monday, November 10th. One investment analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, SOPHiA GENETICS presently has a consensus rating of “Hold” and an average price target of $7.00.

Hedge Funds Weigh In On SOPHiA GENETICS

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Savvy Advisors Inc. acquired a new stake in shares of SOPHiA GENETICS in the 3rd quarter valued at about $48,000. Squarepoint Ops LLC bought a new stake in SOPHiA GENETICS in the 3rd quarter valued at approximately $49,000. GSA Capital Partners LLP acquired a new position in SOPHiA GENETICS during the 3rd quarter worth approximately $59,000. Susquehanna International Group LLP bought a new position in shares of SOPHiA GENETICS during the 3rd quarter worth approximately $88,000. Finally, Silverberg Bernstein Capital Management LLC raised its holdings in shares of SOPHiA GENETICS by 31.8% in the second quarter. Silverberg Bernstein Capital Management LLC now owns 45,715 shares of the company’s stock valued at $142,000 after purchasing an additional 11,040 shares during the last quarter. 31.59% of the stock is owned by institutional investors and hedge funds.

SOPHiA GENETICS Trading Down 0.2%

SOPHiA GENETICS stock traded down $0.01 during mid-day trading on Wednesday, hitting $4.72. 2,240 shares of the company’s stock were exchanged, compared to its average volume of 81,743. SOPHiA GENETICS has a fifty-two week low of $2.58 and a fifty-two week high of $5.30. The company has a quick ratio of 2.62, a current ratio of 2.80 and a debt-to-equity ratio of 0.78. The firm has a market capitalization of $318.98 million, a P/E ratio of -10.26 and a beta of 1.10. The company’s 50 day simple moving average is $4.61 and its 200-day simple moving average is $3.91.

SOPHiA GENETICS (NASDAQ:SOPH) last announced its quarterly earnings results on Tuesday, November 4th. The company reported ($0.30) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.20) by ($0.10). SOPHiA GENETICS had a negative return on equity of 37.75% and a negative net margin of 41.13%.The business had revenue of $19.46 million during the quarter, compared to the consensus estimate of $18.13 million. On average, equities analysts anticipate that SOPHiA GENETICS will post -0.96 earnings per share for the current year.

SOPHiA GENETICS Company Profile

SOPHiA GENETICS SA is a data-driven medicine company founded in 2011 and headquartered in La Tène, Switzerland. The firm develops and operates a cloud-native software platform designed to standardize and analyze complex genomic and radiomic data. Its core offering, the SOPHiA DDM™ platform, leverages artificial intelligence and machine learning algorithms to help healthcare institutions, laboratories and biopharmaceutical partners derive actionable insights from next-generation sequencing and medical imaging datasets.

The SOPHiA DDM™ platform supports a range of clinical applications, including oncology, hereditary diseases and rare genetic disorders.